937046-96-3Relevant academic research and scientific papers
Preparation method 7-bromopyrrolo [2,1-f][1, 2, 4]-thiazine -4- amine (by machine translation)
-
, (2020/03/12)
[, ] The preparation method 7 - of [2,1 - f][1, 2, 4]-(, amino - ((((((((aopipelineao :1) aminopyrrolo 2,5 - thiopyrrole I,) obtained by reacting the intermediate 1 - Boc - 1 - with the formamidine in the following step ;2) can obtain the intermediate I (II, amino-(EC 1 - Boc - 1 -) to obtain the intermediate ;3), namely, II amino-(III, aminopyrrolopyrrole - 2 2-methanonitrile hydrochloride 1 -) to form the intermediate ;4) through the reaction of the intermediates III and the bromination reagent to obtain a final product IV, of the present invention. in an acidic condition and reacting the intermediate body with the bromination reagent. to obtain a final product (4 -aminopyrrolopyridine - 4 4) intermediate, [2,1 - f][1, 2, 4] [2,1 - f][1, 2, 4] obtained by the reaction of the intermediate body with the. bromination reagent and ;5) amino- pyrrolidine. IV-amine,aminopyrroyl hydrochloride 7 . (by machine translation)
THE MONOHYDRATE OF ROGARATINIB HYDROCHLORIDE AND SOLID STATES THEREOF
-
, (2020/08/22)
Compound (III) which is the crystalline form of [4-{[4-amino-6-(methoxymethyl)-5-(7-methoxy-5-methyl-l-benzothiophen-2-yl)pyrrolo[2, -f] [ 1,2,4]triazin-7-yl]methyl}piperazin-2-one hydrochloride] which is the monohydrate, processes for its preparation, pharmaceutical compositions comprising it and its use in the control of disorders, including cancer.
CDK kinase inhibitors
-
, (2020/12/30)
The invention discloses a compound with the general formula (I) and a salt thereof, wherein the compound can be taken as inhibitors of CDK kinase, particularly CDK4/6 kinase, and all variables are defined in the invention. The compound can be used for treating or preventing diseases such as cancer. The present application also relates to pharmaceutical compositions comprising the compound of formula (I).
FGFR INHIBITOR AND MEDICAL APPLICATION THEREOF
-
Paragraph 0171-0173, (2020/07/07)
Provided is a FGFR inhibitor, designating a compound represented by formula (I) or a pharmaceutically acceptable salt thereof. Also provided is the application of a drug for treating solid tumors, such as FGFR related diseases.
Discovery of Rogaratinib (BAY 1163877): a pan-FGFR Inhibitor
Collin, Marie-Pierre,Lobell, Mario,Hübsch, Walter,Brohm, Dirk,Schirok, Hartmut,Jautelat, Rolf,Lustig, Klemens,B?mer, Ulf,V?hringer, Verena,Héroult, Mélanie,Grünewald, Sylvia,Hess-Stumpp, Holger
, p. 437 - 445 (2018/02/21)
Rogaratinib (BAY 1163877) is a highly potent and selective small-molecule pan-fibroblast growth factor receptor (FGFR) inhibitor (FGFR1–4) for oral application currently being investigated in phase 1 clinical trials for the treatment of cancer. In this publication, we report its discovery by de novo structure-based design and medicinal chemistry optimization together with its pharmacokinetic profile.
HETEROCYCLIC COMPOUNDS AS JANUS KINASE INHIBITORS
-
, (2013/03/28)
The invention provides compounds of formula I: (I) or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula I, processes for preparing com-pounds of formula I, intermediates useful for preparing com-pounds of formula I and therapeutic methods for suppressing an immune response or treating cancer, including a hematologic malignancy, using compounds of formula I
HETEROCYCLIC COMPOUNDS AS JANUS KINASE INHIBITORS
-
, (2011/12/14)
The invention provides compounds of formula I: or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula I, intermediates useful for preparing compounds of formula I and therapeutic methods for suppressing an immune response or treating cancer or a hematologic malignancy using compounds of formula I.
THERAPEUTIC AGENTS
-
Page/Page column 29; 33-34, (2010/04/03)
The invention provides a compound of formula (I): wherein R1, and W have any of the values defined in the application; or a salt thereof. The compounds and salts thereof have beneficial therapeutic properties (e.g. immunosuppressant properties).
PYRROLOTRIAZINE COMPOUNDS
-
Page/Page column 57, (2010/11/17)
A compound of formula (I), wherein all symbols have the same meanings as defined in the specification; a salt thereof, a solvate thereof, an N-oxide thereof, or a prodrug thereof, has a Btk inhibitory activity, and is useful as a method for preventing and
SUBSTITUTED 4-AMINO-PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS
-
Page/Page column 253-254, (2008/06/13)
This invention relates to novel pyrrozolotriazine compounds, pharmaceutical compositions containing such compounds and the use of those compounds and compositions for the prevention and/or treatment of hyper-proliferative disorders and diseases associated with angiogenesis.
